Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain

Neuroscience Letters

Volumn 503, Issue 2, 2011, Pages 110-114

  Akamatsu, Yosuke ^a   Saito, Atsushi ^b   Fujimura, Miki ^c   Shimizu, Hiroaki ^b   Mekawy, Moataz ^a   Hasumi, Keiji ^d   Tominaga, Teiji ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOHNAN HOSPITAL   (Japan)

^c SENDAI CITY MEDICAL CENTER   (Japan)

^d TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Matrix metalloproteinase 9; Reactive oxygen species; Stachybotrys microspora triprenyl phenol 7; Transient focal cerebral ischemia (tFCI)

Indexed keywords

3 NITROTYROSINE; FIBRINOLYTIC AGENT; GELATINASE B; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; STACHYBOTRYS MICROSPORA TRIPRENYL PHENOL 7; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; STACHYBOTRYS; STACHYBOTRYS MICROSPORA; TRANSIENT FOCAL CEREBRAL ISCHEMIA;

ANIMALS; BENZOPYRANS; BLOTTING, WESTERN; BRAIN INJURIES; FIBRINOLYTIC AGENTS; ISCHEMIC ATTACK, TRANSIENT; MALE; MATRIX METALLOPROTEINASE 9; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; STACHYBOTRYS; SUPEROXIDES; TYROSINE;

EID: 80052952425     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.08.018     Document Type: Article

References (30)

1. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., Lo E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 2000, 20:1681-1689.
2. Bindokas V.P., Jordan J., Lee C.C., Miller R.J. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J. Neurosci. 1996, 16:1324-1336.
3. Chan P.H. Role of oxidants in ischemic brain damage. Stroke 1996, 27:1124-1129.
4. Fujimura M., Morita-Fujimura Y., Murakami K., Kawase M., Chan P.H. Cytosolic redistribution of cytochrome c after transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 1998, 18:1239-1247.
5. Fujimura M.M., Gasche Y., Morita-Fujimura Y., Copin J.C., Massengale J., Kawase M., Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999, 842:92-100.
6. Gasche Y., Copin J.C., Sugawara T., Fujimura M., Chan P.H. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2001, 21:1393-1400.
7. Heo J.H., Lucero J., Abumiya T., Koziol J.A., Copeland B.R., del Zoppo G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1999, 19:624-633.
8. Hu W., Ohyama S., Hasumi K. Activation of fibrinolysis by SMTP-7 and -8, novel staplabin analogs with a pseudosymmetric structure. J. Antibiot. (Tokyo) 2000, 53:241-247.
9. Kaplan B., Brint S., Tanabe J., Jacewicz M., Wang X.J., Pulsinelli W. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. Stroke 1991, 22:1032-1039.
10. Kaur J., Zhao Z., Klein G.M., Lo E.H., Buchan A.M. The neurotoxicity of tissue plasminogen activator?. J. Cereb. Blood Flow Metab. 2004, 24:945-963.
11. Koizumi J., Yoshida Y., Nakazawa T., Ooneda G. Experimental studies of ischemic brain edema: 1. A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area, Japan. J. Stroke 1986, 8:1-8.
12. Kondo T., Li Y., Sato S., Murakami K., Copin J.C., Huang T.T., Epstein C.J., Chan P.H. Subcellular localization of superoxide anions following focal cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab. [Suppl.] 1997, 17:5102.
13. Leach M.J., Swan J.H., Eisenthal D., Dopson M., Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993, 24:1063-1067.
14. Miyazaki T., Kimura Y., Ohata H., Hashimoto T., Shibata K., Hasumi K., Honda K. Distinct effects of tissue-type plasminogen activator and SMTP-7 on cerebrovascular inflammation following thrombolytic reperfusion. Stroke 2011, 42:1097-1104.
15. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribo M., Quintana M., Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
16. Mun-Bryce S., Rosenberg G.A. Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab. 1998, 18:1163-1172.
17. Planas A.M., Sole S., Justica C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol. Dis. 2001, 8:834-846.
18. Robinson K.M., Janes M.S., Pehar M., Monette J.S., Ross M.F., Hagen T.M. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15038-21504.
19. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Stroke 1998, 29:1020-1030.
20. Shibata K., Hashimoto T., Nobe K., Hasumi K., Honda K. A novel finding of a low molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice. Naunyn-Schmiedebergs Arch. Pharmacol. 2010, 382:245-253.
21. Shinohara C., Hasumi K., Hatsumi W., Endo A. Staplabin, a novel fungal triprenyl phenol which stimulates the binding of plasminogen to fibrin and U937 cells. J. Antibiot. (Tokyo) 1996, 49:961-966.
22. Suzuki Y., Nagai N., Umemura K., Collen D., Lijnen R. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J. Thromb. Haemost. 2007, 5:11732-11739.
23. Suzuki Y.Y., Nagai N., Umemura K. Novel situations of endothelial injury in stroke mechanisms of stroke and strategy of drug development: intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator. J. Pharmacol. Sci. 2011, 116:25-29.
24. Takayasu R., Hasumi K., Shinohara C., Endo A. Enhancement of fibrin binding and activation of plasminogen by staplabin through induction of conformational change in plasminogen. FEBS Lett. 1997, 418:58-62.
25. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
26. Wang X., Asahi M., Lo E.H. Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal. Neurosci. Lett. 1999, 274:79-82.
27. Wang X., Tsuji K., Lee S.R., Ning M., Furie K.L., Buchan A.M., Buchan A.M., Lo E.H. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004, 35(Suppl. 1):2726-2730.
28. Wolin M.S. Interactions of oxidants with vascular signaling systems. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1430-1442.
29. Zhang N., Komine-Kobayashi M., Tanaka R., Liu M., Mizuno Y., Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005, 36:2220-2225.
30. Zhao H. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic. Biol. Med. 2003, 34:1359-1368.